Franklin Street Advisors Inc. NC Sells 12,558 Shares of Medtronic PLC $MDT

Franklin Street Advisors Inc. NC lowered its holdings in Medtronic PLC (NYSE:MDT) by 24.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,313 shares of the medical technology company’s stock after selling 12,558 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Medtronic were worth $3,776,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Artisan Partners Limited Partnership lifted its stake in Medtronic by 2.6% in the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after acquiring an additional 31,314 shares during the last quarter. SageView Advisory Group LLC lifted its stake in Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock valued at $2,305,000 after acquiring an additional 15,062 shares during the last quarter. CSM Advisors LLC lifted its stake in Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock valued at $27,169,000 after acquiring an additional 33,167 shares during the last quarter. UMB Bank n.a. lifted its stake in Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after acquiring an additional 54,898 shares during the last quarter. Finally, Applied Finance Capital Management LLC acquired a new stake in Medtronic in the third quarter valued at $1,308,000. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.26% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Leerink Partners reiterated an “outperform” rating and issued a $119.00 price target on shares of Medtronic in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Piper Sandler cut their price target on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research note on Wednesday, April 1st. Finally, CICC Research assumed coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.10.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands robotic/surgical addressable market — Medtronic received U.S. FDA clearance for its AI-enabled Stealth AXiS system for cranial and ENT procedures, extending the platform beyond spine and broadening opportunities in computer-assisted and robotic surgery. This is a clear product-side growth catalyst for surgical robotics and navigation adoption. Assessing Medtronic Valuation After Stealth AXiS FDA Clearance
• Positive Sentiment: Market tailwinds in core device markets — industry reports highlight multi-year growth in anesthesia/respiratory and lung-cancer surgery markets, with Medtronic named among leading vendors; these secular trends support steady revenue opportunities for MDT’s device franchises. Anesthesia & Respiratory Market Report Lung Cancer Surgery Market
• Neutral Sentiment: Investor note and price action coverage — market write-ups (e.g., Zacks) point to MDT’s intraday move and recent momentum; useful for short-term sentiment tracking but largely descriptive. Zacks: What Investors Need to Know
• Neutral Sentiment: Mixed analyst adjustments — several firms trimmed price targets (Evercore, Citi, others) but mostly kept positive/neutral ratings (buy/outperform/hold). That leaves medium-term upside in some models but increases short-term uncertainty. Evercore PT Adjustment Citi PT Adjustment
• Negative Sentiment: Stifel trims target citing MiniMed IPO impacts — Stifel cut its price target to $95 and flagged transaction-related effects from the recent MiniMed IPO as a reason for lowering near-term expectations; that raises near-term analyst-model risk and may weigh on sentiment. Stifel Cuts MDT Target to $95
• Negative Sentiment: Competitive pressure in cardiac rhythm devices — Johnson & Johnson launched an enhanced pulsed-field ablation device in Europe, signaling faster product rollouts from competitors in electrophysiology that could pressure share gains in select cardiac franchises. J&J launches enhanced PFA device

Medtronic Price Performance

Shares of MDT opened at $88.65 on Thursday. The firm has a market capitalization of $113.81 billion, a PE ratio of 24.69, a PEG ratio of 2.24 and a beta of 0.75. The company’s 50-day moving average is $93.66 and its 200-day moving average is $96.07. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).